Literature DB >> 9205326

Outcomes system implementation for subacute care.

L Crist1.   

Abstract

The emergence of subacute care, seen as a cost-effective alternative to other, more expensive settings, is an important option for case managers. The current, rapid growth of subacute care, the diversity of subacute programs, the differences in patient types, and the lack of consistent standards to define subacute care illustrate the critical need for the case manager's role in balancing quality and cost. The lack of solid clinical outcomes data for patients treated in subacute care make it difficult for case managers to assess quality. Outcomes data, as a measurable dimension of quality, may include clinical effectiveness measures, associated costs, and patient/family satisfaction. Outcomes data can be used as a tool by the case manager to facilitate the coordination of patient care. Although there is an increased consumer interest in outcomes across all health care modalities, there is limited outcomes research available to document the efficacy of subacute care. As the pressure increases for outcomes data on subacute care by consumers and payers, efforts toward facility implementation of outcomes systems to assess subacute care are growing. The unique challenges to outcomes implementation in a skilled nursing facility-based setting are discussed, and strategies for successful implementation are presented. Basic subacute outcomes implementation issues of organizational support, staff participation, and data collection are reviewed. Ideas for case management involvement with facility implementation are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9205326

Source DB:  PubMed          Journal:  Nurs Case Manag        ISSN: 1084-3647


  1 in total

1.  Implementation of a delirium assessment tool in the ICU can influence haloperidol use.

Authors:  Mark van den Boogaard; Peter Pickkers; Hans van der Hoeven; Gabriel Roodbol; Theo van Achterberg; Lisette Schoonhoven
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.